<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00179413</url>
  </required_header>
  <id_info>
    <org_study_id>2001P000002</org_study_id>
    <nct_id>NCT00179413</nct_id>
  </id_info>
  <brief_title>Study of Long-term Peg Intron vs. Colchicine in Non-responders.</brief_title>
  <acronym>COPILOT</acronym>
  <official_title>Phase IV Study of Long Term Peg-Intron for Patients Who Have Failed to Respond to Rebetron/Interferon With Advanced Fibrosis and Cirrhosis Secondary to Hepatitis C- The Copilot Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Schering-Plough</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Beth Israel Deaconess Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study Peg-Intron will be tested to see if it will give better results than
      Colchicine. At this time, there is currently no recommended maintenance treatment for
      patients who have failed to respond to Interferon/Rebetron/Peg Intron and have advanced
      fibrosis. The purpose of this study is to compare two treatments to slow down the progression
      of liver disease and to prevent liver failure and liver cancer. The treatment will not cure
      Hepatitis C, but is being evaluated to see if it can slow down disease progression.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We are proposing a randomized trial of Peg-Intron 0.5mcg per kg weekly versus colchicine
      0.6mg bid in prior non-responders to Interferon, Rebetron, PegIntron, or PegIntron &amp;
      Ribavirin or any third agent such as Pegasys, CellCept, Amantadine with advanced
      fibrosis/cirrhosis. The specific aims of this proposal are to evaluate the role of long term
      Peg-Intron therapy on the natural history of patients with advanced chronic HCV infection
      with a primary focus on prevention of hepatic decompensation, progression of fibrosis and
      hepatoma development.

      The study design will focus on 3 monthly clinical evaluation for decompensation of liver
      function, rigorous clinical screening for development of hepatocellular cancer and liver
      biopsies for determination of progression of liver fibrosis every second year.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 15, 2000</start_date>
  <completion_date type="Actual">March 3, 2010</completion_date>
  <primary_completion_date type="Actual">December 31, 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determination of the Effect of PEG-Intron 0.5mg Per kg Weekly sc Versus Colchicine 0.6mg Bid Daily on:</measure>
    <time_frame>4 years</time_frame>
    <description>number of patients with a liver related outcomes including: mortality, liver transplant, variceal or portal hypertensive bleeding,Development of jaundice, ascites or encephalopathy with an increase in CPT of &gt; 2 points and development of hepatoma</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Safety and Tolerability of Long Term Maintenance PEG-Intron in Patients With Cirrhosis</measure>
    <time_frame>4 years</time_frame>
    <description>Defined as the number of patients who discontinued therapy due to an adverse event side</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of Portal Hypertension</measure>
    <time_frame>4 years</time_frame>
    <description>Number of patients who develop endoscopic evidence of varices over 4 year period</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">549</enrollment>
  <condition>Hepatitis C Virus</condition>
  <condition>Advanced Fibrosis</condition>
  <condition>Cirrhosis</condition>
  <arm_group>
    <arm_group_label>PEG-Intron</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PEG-Intron 0.5mcg/kg once a week SC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Colchicine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.6mg twice a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEG -Intron</intervention_name>
    <arm_group_label>PEG-Intron</arm_group_label>
    <other_name>PEG interferon Alfa-2b 0.5mcg/kg weekly</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colchicine</intervention_name>
    <description>0.6mg twice a day</description>
    <arm_group_label>Colchicine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  *Adult male or female, age 18 to 75 years

               -  HCV RNA positive by PCR

               -  Previous treatment with at least three months of interferon or interferon /
                  Ribavirin. Patients should have had no interferon for at least 2 months prior to
                  enrollment.

                    1. Non-responders are identified by failure to clear virus by PCR after a
                       minimum 3-month course of treatment and who have been off treatment for at
                       least 2 months with a positive PCR for HCV prior to entry into the current
                       study, 2) Partial responders have a reduction of 1 long in HCV RNA, but the
                       virus is still detectable, 3) Breakthrough patients have been negative on
                       treatment, but virus appeared while still on treatment, 4) Relapsers are
                       defined as negative PCR at some point during treatment, but virus reoccurred
                       or was detectable by HCV PCR when treatment stopped.

        Patients should have had a liver biopsy showing at least Stage 3 disease prior to being
        considered for this study. A baseline liver biopsy is necessary for inclusion in the study.
        Baseline liver biopsies can be performed within six months of entering the study.

        In patients with cirrhosis and endoscopic evidence of portal hypertension, a biopsy within
        the last 2 years is acceptable as the baseline biopsy. For patients with established
        cirrhosis on liver biopsy and no portal hypertension, a biopsy within 12 months can be used
        as the baseline biopsy if it is available for evaluation by the Pathology core. All these
        patients will still require liver biopsy at 2 years and 4 years. The decision to biopsy at
        2 and 4 years is also a clinical decision and in the presence of clinical progression or
        coagulopathy, or where there may be a risk from liver biopsy, the Investigator should call
        the PI, Dr. Afdhal for a waiver of biopsy. Patients with Ishak Stage 3 and 4 require a
        biopsy within 6 months of randomization.

          -  Hemoglobin &gt;= 11 g/dl in males and 10 g/dl in females

          -  Neutrophil count &gt; 1,500/mm3

          -  Platelets &gt; 50, 000/mm3

        Platelet count: For standard dose of PEG-Intron 0.5mcg/kg platelet count must be greater
        than 70,000. Patients with platelet count 50 - 70,000 can start at 0.25mcg/kg for weeks 0 -
        4. If platelets fall to less than 30,000, stop treatment. If platelets remain &gt; 50,000 at
        week 4, PEG-Intron can be increased to 0.5mcg/kg. Patients randomized to Colchicine with
        platelets 50,000 - 70,000 can be started at standard dose 0.6mg bid po with standard dose
        reduction.

          -  Prothrombin time &lt;= 3secs prolonged compared to control or an equivalent INR &lt; 1.5

          -  Total bilirubin &lt; 3gm/dL

          -  Fasting blood sugar &lt;= 115 mg/dl or within 20% of the upper limit of normal for
             non-diabetic patients

          -  Albumin (&gt; 2.8mg/dl)

          -  Serum creatinine &lt; 1.4 mg/dL

          -  TSH within the normal range (Patients with thyroid disease who are well controlled are
             eligible if the remainder of the inclusion/exclusion criteria are met)

          -  HIV negative.

               -  HBsAg negative

               -  Childs Pugh score of less than or equal to 7

               -  Serum positive for anti-hepatitis C antibodies or HCV RNA.

               -  Alpha-fetoprotein &lt; 100ng/ml with ultrasound negative for focal mass or HCC. For
                  any patient with an Alpha-fetoprotein &gt;100 ng/ml either a triple phase contrast
                  CT scan or MRI with gadolinium must show no focal mass or evidence of HCC

               -  Ultrasound with no evidence of focal mass suggestive of hepatoma (within 6 months
                  of informed consent).

               -  Documentation that sexually active female patients of childbearing potential are
                  practicing adequate contraception during the treatment period. A urine pregnancy
                  test obtained at entry prior to the initiation of treatment must be negative.
                  Female patients must not be breast-feeding. Documentation that sexually active
                  male patients are practicing acceptable methods of contraception during the
                  treatment period.

               -  Written informed consent specific for this protocol has been obtained prior to
                  entry.

        Exclusion Criteria:

          -  Any cause of liver disease based on patient history and biopsy (where applicable)
             other than chronic hepatitis C including but not limited to:

               -  Co-infection with hepatitis B or HIV

               -  Hemochromatosis (confirmed by genetic testing)

               -  Alpha-1 antitrypsin deficiency

               -  Wilson's disease

               -  Renal or liver transplant patients

               -  Autoimmune hepatitis

               -  Alcoholic liver disease

               -  Obesity induced liver disease

               -  Drug related liver disease

        In addition:

          -  Evidence of decompensated liver disease such as a history or presence of ascites, and
             spontaneous encephalopathy. Patients with past bleeding esophageal varices that have
             not bled for more than 1 year can be included.

          -  Hypersensitivity to alpha interferon

          -  Drug related liver disease

          -  Hemoglobinopathies (e.g. Thalassaemia, sickle cell disease).

          -  Patients with clinically significant retinal abnormalities.

          -  Substance abuse, such as alcohol (Â·&gt; 80 gm/day), I.V. drugs and inhaled drugs. If the
             patient has a history of substance abuse, to be considered for inclusion into the
             protocol, the patient must have abstained from using the abused substance for at least
             6 months. Patients on methadone will be allowed in the study with no restrictions as
             is now standard of care in HCV therapy.

          -  Patients with a history of organ transplantation will be excluded.

        Preexisting psychiatric conditions, especially depression, or a history of severe
        psychiatric disorder, such as major psychoses, suicidal ideation and/or suicidal attempt
        are excluded. Patients with a history of mild depression may enter the protocol if they
        meet the following eligibility criterion and are monitored more intensively.

        Mild depression: to include either situational depression of a limited period or depressive
        symptoms, which do not significantly interfere with the patient's work or daily functions.

        Any patient with an active manic element to his/her previous symptom complex will be
        excluded.

        Any known pre-existing medical condition that could interfere with the patient's
        participation in and completion of the study such as:

          -  Pre-existing psychiatric condition, especially severe depression, or a history of
             severe psychiatric disorder

          -  CNS trauma or seizure disorder requiring therapy

          -  Significant cardiac dysfunction in the previous 6 months e.g. angina, CCF,
             hypertension or arrhythmia Patients on treatment are eligible as long as they have
             been symptom free for the previous 6 months.

          -  Poorly controlled diabetes mellitus

          -  Chronic pulmonary disease (e.g. COAD)

          -  Immunologically mediated diseases (e.g. inflammatory bowel disease, SLE, ITP,
             autoimmune hemolytic anemia, scleroderma, rheumatoid arthritis, severe psoriasis)

          -  Clinical gout

          -  Patients with clinically significant retinal abnormalities

          -  Patients with organ transplants

        Any other condition, which in the view of the investigator, would make the patient
        unsuitable for enrolment, or could interfere with the patient participating in and
        completing the protocol are included as well.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nezam H Afdhal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Birmingham Gastroenterology Associates</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UAMS Medical Center</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>34th Street Community Health Center</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93301-1645</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanende-GI Department</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95825</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Associates</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Health Sciences Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Danbury Hospital</name>
      <address>
        <city>Danbury</city>
        <state>Connecticut</state>
        <zip>06810</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bruce Stein, MD</name>
      <address>
        <city>Manchester</city>
        <state>Connecticut</state>
        <zip>06040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connecticut Gastroenterology Consultants</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown University Medical Center</name>
      <address>
        <city>Washington, D.C.</city>
        <state>District of Columbia</state>
        <zip>20007-2197</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Walter Reed Army Medical Center</name>
      <address>
        <city>Washington, D.C.</city>
        <state>District of Columbia</state>
        <zip>20307-5001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bach and Godofsky Infectious Disease</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Clinical Research Consultants</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Associates of South Florida</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Digestive Health Services</name>
      <address>
        <city>Downers Grove</city>
        <state>Illinois</state>
        <zip>60515</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Digestive Disease Associates</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lahey Clinic</name>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <zip>01805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hampshire Gastroenterology</name>
      <address>
        <city>Florence</city>
        <state>Massachusetts</state>
        <zip>01062</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fallon Clinic</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne State University/Haper Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Division Veterans Affairs Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55417</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minnesota Gastroenterology</name>
      <address>
        <city>Plymouth</city>
        <state>Minnesota</state>
        <zip>55446</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Associates</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA New Jersey Healthcare System</name>
      <address>
        <city>East Orange</city>
        <state>New Jersey</state>
        <zip>07018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlantic Gastroenterology</name>
      <address>
        <city>Egg Harbor</city>
        <state>New Jersey</state>
        <zip>08234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florham Park Endoscopy Center</name>
      <address>
        <city>Florham Park</city>
        <state>New Jersey</state>
        <zip>07932</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern New Mexico Gastroenterology</name>
      <address>
        <city>Santa Fe</city>
        <state>New Mexico</state>
        <zip>87505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Sam Moskowitz, MD, PC</name>
      <address>
        <city>Forest Hills</city>
        <state>New York</state>
        <zip>11375</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liberty Medical, LLP</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metro Medical</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peter Varunok, MD</name>
      <address>
        <city>Poughkeepsie</city>
        <state>New York</state>
        <zip>12601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Upstate Medical Center</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Temple University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albert Einstein Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guthrie Research Foundation</name>
      <address>
        <city>Sayre</city>
        <state>Pennsylvania</state>
        <zip>18840</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Gastroenterologists</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roger Williams Medical Center</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nashville Gastroenterology Specialists Incorporated</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Gastroenterology</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78745</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>G.I. and Liver Associates</name>
      <address>
        <city>Granbury</city>
        <state>Texas</state>
        <zip>76048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Digestive Disease Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Transplant Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Science Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 10, 2005</study_first_submitted>
  <study_first_submitted_qc>September 10, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <results_first_submitted>April 13, 2017</results_first_submitted>
  <results_first_submitted_qc>June 11, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 11, 2017</results_first_posted>
  <last_update_submitted>June 11, 2017</last_update_submitted>
  <last_update_submitted_qc>June 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beth Israel Deaconess Medical Center</investigator_affiliation>
    <investigator_full_name>Nezam H. Afdhal</investigator_full_name>
    <investigator_title>Professor of Medicine, Part-time</investigator_title>
  </responsible_party>
  <keyword>hepatitis C</keyword>
  <keyword>cirrhosis</keyword>
  <keyword>interferon</keyword>
  <keyword>colchicine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Peginterferon alfa-2b</mesh_term>
    <mesh_term>Colchicine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>PEG-Intron</title>
          <description>PEG-Intron 0.5mcg/kg once a week SC
PEG -Intron</description>
        </group>
        <group group_id="P2">
          <title>Colchicine</title>
          <description>0.6mg twice a day
Colchicine: 0.6mg twice a day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="282"/>
                <participants group_id="P2" count="267"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="157"/>
                <participants group_id="P2" count="152"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="125"/>
                <participants group_id="P2" count="115"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="87"/>
                <participants group_id="P2" count="95"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PEG-Intron</title>
          <description>PEG-Intron 0.5mcg/kg once a week SC
PEG -Intron</description>
        </group>
        <group group_id="B2">
          <title>Colchicine</title>
          <description>0.6mg twice a day
Colchicine: 0.6mg twice a day</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="282"/>
            <count group_id="B2" value="267"/>
            <count group_id="B3" value="549"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50" spread="8.4"/>
                    <measurement group_id="B2" value="50.4" spread="7.1"/>
                    <measurement group_id="B3" value="50.2" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="167"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="192"/>
                    <measurement group_id="B2" value="190"/>
                    <measurement group_id="B3" value="382"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="72"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="240"/>
                    <measurement group_id="B2" value="227"/>
                    <measurement group_id="B3" value="467"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="282"/>
                    <measurement group_id="B2" value="267"/>
                    <measurement group_id="B3" value="549"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Determination of the Effect of PEG-Intron 0.5mg Per kg Weekly sc Versus Colchicine 0.6mg Bid Daily on:</title>
        <description>number of patients with a liver related outcomes including: mortality, liver transplant, variceal or portal hypertensive bleeding,Development of jaundice, ascites or encephalopathy with an increase in CPT of &gt; 2 points and development of hepatoma</description>
        <time_frame>4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PEG-Intron</title>
            <description>PEG-Intron 0.5mcg/kg once a week SC
PEG -Intron</description>
          </group>
          <group group_id="O2">
            <title>Colchicine</title>
            <description>0.6mg twice a day
Colchicine: 0.6mg twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>Determination of the Effect of PEG-Intron 0.5mg Per kg Weekly sc Versus Colchicine 0.6mg Bid Daily on:</title>
          <description>number of patients with a liver related outcomes including: mortality, liver transplant, variceal or portal hypertensive bleeding,Development of jaundice, ascites or encephalopathy with an increase in CPT of &gt; 2 points and development of hepatoma</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="282"/>
                <count group_id="O2" value="267"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of Safety and Tolerability of Long Term Maintenance PEG-Intron in Patients With Cirrhosis</title>
        <description>Defined as the number of patients who discontinued therapy due to an adverse event side</description>
        <time_frame>4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PEG-Intron</title>
            <description>PEG-Intron 0.5mcg/kg once a week SC
PEG -Intron</description>
          </group>
          <group group_id="O2">
            <title>Colchicine</title>
            <description>0.6mg twice a day
Colchicine: 0.6mg twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Safety and Tolerability of Long Term Maintenance PEG-Intron in Patients With Cirrhosis</title>
          <description>Defined as the number of patients who discontinued therapy due to an adverse event side</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="282"/>
                <count group_id="O2" value="267"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Development of Portal Hypertension</title>
        <description>Number of patients who develop endoscopic evidence of varices over 4 year period</description>
        <time_frame>4 years</time_frame>
        <population>The number of patients at risk include only those patients who at the baseline endoscopy had no evidence of portal hypertension or varices</population>
        <group_list>
          <group group_id="O1">
            <title>PEG-Intron</title>
            <description>PEG-Intron 0.5mcg/kg once a week SC
PEG -Intron</description>
          </group>
          <group group_id="O2">
            <title>Colchicine</title>
            <description>0.6mg twice a day
Colchicine: 0.6mg twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>Development of Portal Hypertension</title>
          <description>Number of patients who develop endoscopic evidence of varices over 4 year period</description>
          <population>The number of patients at risk include only those patients who at the baseline endoscopy had no evidence of portal hypertension or varices</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Four years on treatment</time_frame>
      <desc>Although not included as an Adverse event in the clinical trial design but rather as a primary endpoint, liver disease progression has now been added as an adverse event</desc>
      <group_list>
        <group group_id="E1">
          <title>PEG-Intron</title>
          <description>PEG-Intron 0.5mcg/kg once a week SC
PEG -Intron</description>
        </group>
        <group group_id="E2">
          <title>Colchicine</title>
          <description>0.6mg twice a day
Colchicine: 0.6mg twice a day</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="90" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="79" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="282"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue, asthenia</sub_title>
                <counts group_id="E1" events="31" subjects_affected="31" subjects_at_risk="282"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Disease progression</sub_title>
                <description>Patients who met the primary endpoints of disease progression with liver failure, bleeding or liver cancer</description>
                <counts group_id="E1" events="53" subjects_affected="53" subjects_at_risk="282"/>
                <counts group_id="E2" events="59" subjects_affected="59" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="282"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="257" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="282"/>
                <counts group_id="E2" events="36" subjects_affected="36" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>flu like symptoms</sub_title>
                <counts group_id="E1" events="242" subjects_affected="242" subjects_at_risk="282"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Nezam Afdhal</name_or_title>
      <organization>BIDMC</organization>
      <phone>617632118</phone>
      <email>nafdhal@bidmc.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

